JP4217984B2 - 携帯用イオン導入器 - Google Patents
携帯用イオン導入器 Download PDFInfo
- Publication number
- JP4217984B2 JP4217984B2 JP2005509470A JP2005509470A JP4217984B2 JP 4217984 B2 JP4217984 B2 JP 4217984B2 JP 2005509470 A JP2005509470 A JP 2005509470A JP 2005509470 A JP2005509470 A JP 2005509470A JP 4217984 B2 JP4217984 B2 JP 4217984B2
- Authority
- JP
- Japan
- Prior art keywords
- iontophoresis device
- drug
- portable
- wave
- electrode terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 43
- 150000002500 ions Chemical class 0.000 claims description 28
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 230000000144 pharmacologic effect Effects 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 5
- 210000000689 upper leg Anatomy 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 239000004020 conductor Substances 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 50
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 25
- 229930003268 Vitamin C Natural products 0.000 description 25
- 235000019154 vitamin C Nutrition 0.000 description 25
- 239000011718 vitamin C Substances 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 23
- 210000000056 organ Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 210000004207 dermis Anatomy 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 210000004195 gingiva Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000968 medical method and process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
Description
また、上記従来技術におけるイオン導入器はいずれも電極部を改良したものであり、常時携帯には不向きであり、避妊薬、歯科麻酔・鎮痛薬、痔治療薬、救急創傷治療薬、消炎鎮痛薬、心臓発作抑制薬、喘息発作抑制薬等、応急性・用時適用を要する薬剤の使用には不向きであった。
図1において、1はポケットサイズの携帯用イオン導入器本体、2はスイッチである。3は出力調整ボタンであり、出力調整は4段階で行う。電流は可変で、最大3.0mAとする。周波数と波形の出力調整は図2における出力調整ダイヤル5にて4段階で行う。周波数は1530Hz、波形は矩形波・積分波を主にしたElliptic R波、電流は断続平流とする。極性は+・−を極性調整ボタン4で切り替えを行う。該イオン導入器内には内臓タイマーを有し、設定時間の確認を行うことを可能とする。電源は全世界対応で、充電形式とする。体の各部位、もしくは組織に貼付使用する薬剤含浸パッドを備えた導入側電極端子と対側電極端子を有する。電極端子用のコードは装着し易くためにホック式とする。該携帯用イオン導入器は定電流回路を採用し、抵抗値に関係なく、一定の断続平流の電流を流せるようにする。抵抗値は条件によるが、10kΩまで有効である。本装置のサイズは例えば縦19mm×横33mm×高さ145mmに形成した場合であるが、このサイズに限定されるものではなくよりコンパクト化或いは携帯可能な形状とする。
また、ビタミンCの持続時間において、ビタミンCの最高値に到達すると推定される導入後4時間及び6時間で調べたところ、従来のイオン導入器よりも長い6時間の持続性が認められた。
図2は本発明の一例を示す背面からの斜視図である。
図3は本発明の一例にサスベンダーを具備した状態を示す斜視図である。
図4は本発明の一例において定電流回路として有効抵抗値の試験を行った結果のグラフである。
図5は本発明の一例において定電流回路として有効抵抗値の試験を行った際の条件である。
図6は本発明の一例の仕様である。
図7は本発明の一例の実施例におけるイオン導入の波形である。
Claims (3)
- ポケット型に形成した携帯用イオン導入器本体を肩・腰・背中・太股の群から選ばれる一つまたはそれ以上の体部からベルトで吊るす等の体部への取付手段にて携帯型に形成し、該携帯用イオン導入器本体は断続平流の矩形波・積分波を主にしたElliptic R波形で、周波数が1500から1550Hzの投入手段を備え、前記断続平流の矩形波・積分波を主にしたElliptic R波形が一方の極性において複数回の繰り返し後、該断続平流の矩形波・積分波を主にしたElliptic R波形と同等の逆極性の波形を1回印加する関係を交互に繰返す印加手段を備えるとともに、導入側電極端子と対側電極端子を備え、該2つの電極端子を標的体部と対側体部にそれぞれ装着可能に形成したことを特徴とする携帯用イオン導入器。
- 前記電極端子の表面は金属材・不織布・可塑性電導材の群から選ばれる一つまたはそれ以上の材料からなることを特徴とする請求項1記載の携帯用イオン導入器。
- 皮膚及び、または粘膜の表面から少量ずつ長時間持続的に血管内に浸透させて全身に分布させ臨床薬理効果が発現増強される薬剤を含浸させる薬剤含浸パッドと、該薬剤含浸パッドを介在させて血管が位置している体部の皮膚及び、または粘膜に宛がうイオンの導入側電極端子とを備えたことを特徴とする請求項1又は2記載の携帯用イオン導入器。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/013079 WO2005035051A1 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器及び薬剤投与方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005035051A1 JPWO2005035051A1 (ja) | 2006-12-21 |
JP4217984B2 true JP4217984B2 (ja) | 2009-02-04 |
Family
ID=34430865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005509470A Expired - Lifetime JP4217984B2 (ja) | 2003-10-10 | 2003-10-10 | 携帯用イオン導入器 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4217984B2 (ja) |
AU (1) | AU2003271179A1 (ja) |
WO (1) | WO2005035051A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012063883A1 (ja) | 2010-11-09 | 2012-05-18 | 株式会社資生堂 | コンテンツ再生装置、コンテンツ再生方法、及び記録媒体 |
WO2014054459A1 (ja) | 2012-10-05 | 2014-04-10 | 株式会社資生堂 | 美容機器、通電方法及び記録媒体 |
WO2014068698A1 (ja) * | 2012-10-31 | 2014-05-08 | 株式会社インディバ・ジャパン | 脂肪滴・セルライト抑制装置 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2839279B2 (ja) * | 1989-03-16 | 1998-12-16 | 久光製薬株式会社 | イオントフォレーゼ用デバイス |
JPH09103496A (ja) * | 1995-10-12 | 1997-04-22 | Etsuko Nozoe | イオン浸透治療器 |
IT1315207B1 (it) * | 1999-06-09 | 2003-02-03 | Antonino D Africa | Dispositvo e metodo per il trasporto molecolare transdermico. |
CA2325195A1 (en) * | 1999-12-09 | 2001-06-09 | Iomed, Inc. | Connection system including a tether for an iontophoretic drug delivery device |
-
2003
- 2003-10-10 AU AU2003271179A patent/AU2003271179A1/en not_active Abandoned
- 2003-10-10 JP JP2005509470A patent/JP4217984B2/ja not_active Expired - Lifetime
- 2003-10-10 WO PCT/JP2003/013079 patent/WO2005035051A1/ja active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012063883A1 (ja) | 2010-11-09 | 2012-05-18 | 株式会社資生堂 | コンテンツ再生装置、コンテンツ再生方法、及び記録媒体 |
KR20160027994A (ko) | 2010-11-09 | 2016-03-10 | 가부시키가이샤 시세이도 | 콘텐츠 재생장치, 콘텐츠 재생방법 및 기록매체 |
US9795783B2 (en) | 2010-11-09 | 2017-10-24 | Shiseido Company, Ltd. | Content reproduction apparatus, content reproduction method, and storage medium |
WO2014054459A1 (ja) | 2012-10-05 | 2014-04-10 | 株式会社資生堂 | 美容機器、通電方法及び記録媒体 |
US9981125B2 (en) | 2012-10-05 | 2018-05-29 | Shiseido Company, Ltd. | Cosmetic device, method of applying current, and storage medium |
WO2014068698A1 (ja) * | 2012-10-31 | 2014-05-08 | 株式会社インディバ・ジャパン | 脂肪滴・セルライト抑制装置 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005035051A1 (ja) | 2006-12-21 |
AU2003271179A1 (en) | 2005-04-27 |
WO2005035051A1 (ja) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5160316A (en) | Iontophoretic drug delivery apparatus | |
US6238381B1 (en) | Iontophoretic treatment system | |
US4786277A (en) | Electrodes, electrode assemblies, methods, and systems for tissue stimulation | |
CA2218369C (en) | Transdermal electrotransport delivery of fentanyl and sufentanil | |
US4702732A (en) | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands | |
EP0483883A1 (en) | Iontophoretic treatment system | |
US8295924B2 (en) | Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions | |
WO1997027899A9 (en) | Iontophoretic treatment system | |
JP2000510012A (ja) | イオン導入法による薬剤の供給装置およびその使用方法 | |
Garg et al. | Iontophoresis: drug delivery system by applying an electrical potential across the skin | |
US20200179314A1 (en) | Lidocaine Patch and Methods of Use Thereof | |
JP2001505197A (ja) | リドカイン及びエピネフリンの電気的補助投与のための製剤 | |
SU1003853A1 (ru) | Устройство дл электрофонофореза | |
JPH09503136A (ja) | イオン導入ドラッグデリバリーシステム及び方法 | |
JP4217984B2 (ja) | 携帯用イオン導入器 | |
US6139537A (en) | Iontophoretic treatment system | |
Prausnitz et al. | Methods for in vivo tissue electroporation using surface electrodes | |
Dehghan et al. | Advances in iontophoresis for drug delivery | |
US6235013B1 (en) | Iontophoretic treatment system | |
US20100331761A1 (en) | Apparatus and Method for Dermatological Wound Healing | |
Anisimov et al. | Development of a portable device for iontophoresis | |
RU2157257C1 (ru) | Способ лечения заболеваний заднего отрезка глаза человека методом эндоназального электрофореза и установка для его осуществления | |
Gazelius | Iontophoresis-theory | |
Vranić | Iontophoresis: fundamentals, developments and application | |
Adedapo et al. | Iontophoresis: Anemergingapproachtotransdermal drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050309 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20050309 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070831 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080610 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080708 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080930 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081029 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4217984 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111121 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121121 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121121 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131121 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |